The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Completing the $7.2 billion buyout of AspenTech "marks a key milestone in the final phase of Emerson's portfolio ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...

Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

The completed campus near Salt Lake City will have more than 1 million sq ft of data centers with a combined 175-MW capacity.

Investing.com -- Shares of Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) tumbled 55% after the company announced topline results from its PROGRESS Phase 2b study, which evaluated pilavapadin in ...

Burnaby Hospital’s brand new pavilion will open this year, according to a Burnaby Hospital redevelopment project delegation ...